Powered by

Proteostasis Added to the Russell 3000® Index

Jun 25, 2018 - PR Newswire

 Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced that the Company's stock was added to the Russell 3000®Index when the Russell Investment Group reconstituted its family of U.S. indexes following market close on June 22, 2018.

"Inclusion in the Russell 3000 Index increases liq...